RegulatoryCompany release

AEON Biopharma gets FDA Type 2b feedback on ABP-450 biosimilar route to BOTOX

🇺🇸 AEON Biopharma, Inc. (AEON) · Mon 16 Nov 2026

The US regulator has agreed in principle to a two-stage pharmacodynamic study and signalled that earlier Daewoong clinical data could be supportive, subject to bridging.

AEON Biopharma said on 16 November 2026, alongside its third-quarter results, that it has received minutes from a Type 2b meeting with the US Food and Drug Administration on developing ABP-450 as a biosimilar to BOTOX.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): AEON Biopharma, Inc. ↗

Article written by VigiEye from the official source (AEON Biopharma, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →